Aquestive Therapeutics, Inc.: shareholders and insiders

AQSTNASDAQHealthcare · Pharmaceutical Preparations

Price

$3.46

November 20, 2026Market cap $422M

What Ploutos Investor adds for Aquestive Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 21, 2025 to Nov 16, 2026, from their own Form 4 filings.

23 Form 4s

Bought on the market

$99.3K

1 person

Sold on the market

$2.4M

9 people

From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan32%
  • The rest68%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $99.3K by 1 person·sold $2.4M by 9 people

  • 2025: no buys, no sales
  • 2026: bought $99.3K by 1 person, sold $2.4M by 9 people
  • Nov 12, 2026Matthew W. DavisChief Development Officer
    Kind10b5-1
  • Nov 10, 2026Richard J DalyDirector
    Kind
  • Nov 10, 2026Richard J DalyDirector
    Kind
  • Nov 10, 2026Matthew W. DavisChief Development Officer
    Kind
  • Oct 21, 2026John CochranDirector
    Kind
  • Oct 15, 2026Daniel BarberPresident and CEO
    Kind10b5-1
  • Sep 15, 2026Daniel BarberPresident and CEO
    Kind10b5-1
  • Sep 9, 2026Sherry KorczynskiChief Commercial Officer
    Kind10b5-1
  • Sep 9, 2026Sherry KorczynskiChief Commercial Officer
    Kind10b5-1
  • Sep 9, 2026Peter E. BoydChief People Officer
    Kind
  • Sep 8, 2026Daniel BarberPresident and CEO
    Kind
  • Sep 3, 2026Cassie JungChief Operating Officer
    Kind
  • Aug 17, 2026Daniel BarberPresident and CEO
    Kind10b5-1
  • Aug 14, 2026Sherry KorczynskiChief Commercial Officer
    Kind
  • Jul 16, 2026Daniel BarberPresident and CEO
    Kind10b5-1
  • Jul 15, 2026Daniel BarberPresident and CEO
    Kind10b5-1
  • Jun 23, 2026Julie KropDirector
    Kind10b5-1
  • Jun 23, 2026Julie KropDirector
    Kind10b5-1
  • Jun 15, 2026Daniel BarberPresident and CEO
    Kind10b5-1
  • Jun 8, 2026Sherry KorczynskiChief Commercial Officer
    Kind
  • May 15, 2026Daniel BarberPresident and CEO
    Kind10b5-1
  • Mar 10, 2026Cassie JungChief Operating Officer
    Kind
  • Mar 10, 2026Sherry KorczynskiChief Commercial Officer
    Kind
  • Mar 10, 2026A Ernest Toth JrChief Financial Officer
    Kind
  • Mar 10, 2026Melina CioffiSVP, Regulatory Affairs
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 9, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by AQST's officers and directors from 2018 up to November 20, 2025, 8 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

3 Holders over 5%Oct 7, 2026 Latest filing
  • Bass Edward Pwith 1 more person
    Share of class7.50%
  • BlackRock, Inc.
    Share of class6.40%
  • RTW Investments, LPwith 1 more person
    Share of class5.20%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Bratton Douglas K0.60%Oct 7, 202613G/A
  • Venrock Healthcare Capital Partners III, L.P.2.90%Feb 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Citadel Advisors (Griffin)
    In the quarter+79%
  • Millennium Mgmt (Englander)
    In the quarter
  • D.E. Shaw
    In the quarter×30.9
  • Renaissance Technologies
    In the quarter+34%
  • AQR Capital
    In the quarter+19%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 22.6% of its shares outstanding were held short, -4.0% since the report before.

Shares held short
27.60M
22.6%
Since the report before28.75M on Sep 30, 2026
-4.0%
13.9
1.99M
More days to cover thanof 4,578 US-listed companies with enough volume
97%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 1.95M
  • Nov 15, 2023: Shares held short 1.92M
  • Nov 30, 2023: Shares held short 1.88M
  • Dec 15, 2023: Shares held short 2.07M
  • Dec 29, 2023: Shares held short 2.05M
  • Jan 12, 2024: Shares held short 1.90M
  • Jan 31, 2024: Shares held short 1.74M
  • Feb 15, 2024: Shares held short 1.99M
  • Feb 29, 2024: Shares held short 1.81M
  • Mar 15, 2024: Shares held short 2.32M
  • Mar 28, 2024: Shares held short 2.27M
  • Apr 15, 2024: Shares held short 4.01M
  • Apr 30, 2024: Shares held short 5.27M
  • May 15, 2024: Shares held short 6.18M
  • May 31, 2024: Shares held short 6.70M
  • Jun 14, 2024: Shares held short 7.18M
  • Jun 28, 2024: Shares held short 7.63M
  • Jul 15, 2024: Shares held short 10.37M
  • Jul 31, 2024: Shares held short 10.79M
  • Aug 15, 2024: Shares held short 10.79M
  • Aug 30, 2024: Shares held short 10.80M
  • Sep 13, 2024: Shares held short 10.80M
  • Sep 30, 2024: Shares held short 11.06M
  • Oct 15, 2024: Shares held short 10.79M
  • Oct 31, 2024: Shares held short 10.14M
  • Nov 15, 2024: Shares held short 9.97M
  • Nov 29, 2024: Shares held short 10.15M
  • Dec 13, 2024: Shares held short 9.65M
  • Dec 31, 2024: Shares held short 10.48M
  • Jan 15, 2025: Shares held short 11.79M
  • Jan 31, 2025: Shares held short 11.09M
  • Feb 14, 2025: Shares held short 9.98M
  • Feb 28, 2025: Shares held short 9.98M
  • Mar 14, 2025: Shares held short 10.23M
  • Mar 31, 2025: Shares held short 10.02M
  • Apr 15, 2025: Shares held short 9.87M
  • Apr 30, 2025: Shares held short 9.41M
  • May 15, 2025: Shares held short 9.84M
  • May 30, 2025: Shares held short 11.14M
  • Jun 13, 2025: Shares held short 12.00M
  • Jun 30, 2025: Shares held short 11.18M
  • Jul 15, 2025: Shares held short 10.01M
  • Jul 31, 2025: Shares held short 9.44M
  • Aug 15, 2025: Shares held short 8.41M
  • Aug 29, 2025: Shares held short 9.27M
  • Sep 15, 2025: Shares held short 8.88M
  • Sep 30, 2025: Shares held short 11.58M
  • Oct 15, 2025: Shares held short 12.25M
  • Oct 31, 2025: Shares held short 14.74M
  • Nov 14, 2025: Shares held short 19.20M
  • Nov 28, 2025: Shares held short 19.83M
  • Dec 15, 2025: Shares held short 21.92M
  • Dec 31, 2025: Shares held short 24.14M
  • Jan 15, 2026: Shares held short 20.30M
  • Jan 30, 2026: Shares held short 20.39M
  • Feb 13, 2026: Shares held short 20.04M
  • Feb 27, 2026: Shares held short 19.95M
  • Mar 13, 2026: Shares held short 17.68M
  • Mar 31, 2026: Shares held short 17.56M
  • Apr 15, 2026: Shares held short 15.52M
  • Apr 30, 2026: Shares held short 15.50M
  • May 15, 2026: Shares held short 15.03M
  • May 29, 2026: Shares held short 15.24M
  • Jun 15, 2026: Shares held short 14.80M
  • Jun 30, 2026: Shares held short 16.00M
  • Jul 15, 2026: Shares held short 16.67M
  • Jul 31, 2026: Shares held short 18.05M
  • Aug 14, 2026: Shares held short 20.95M
  • Aug 31, 2026: Shares held short 25.48M
  • Sep 15, 2026: Shares held short 27.16M
  • Sep 30, 2026: Shares held short 28.75M
  • Oct 15, 2026: Shares held short 27.60M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading58.1% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 58.1% of the shares in the reported trades were short sales, against 57.7% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
58.1%
The 14 beforeOct 14, 2026 – Nov 2, 2026
57.7%
Change
+0.4 pts
Short sales a dayon average, of 1.37M shares
795.9K
More than atof 3,674 US-listed companies, same days
77%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 52.1%
  • Oct 15, 2026: Short sales 53%
  • Oct 16, 2026: Short sales 58.3%
  • Oct 19, 2026: Short sales 73.7%
  • Oct 20, 2026: Short sales 40.5%
  • Oct 21, 2026: Short sales 48.7%
  • Oct 22, 2026: Short sales 52.7%
  • Oct 23, 2026: Short sales 65.6%
  • Oct 26, 2026: Short sales 61%
  • Oct 27, 2026: Short sales 48.6%
  • Oct 28, 2026: Short sales 51.1%
  • Oct 29, 2026: Short sales 61.9%
  • Oct 30, 2026: Short sales 62.9%
  • Nov 2, 2026: Short sales 63.4%
  • Nov 3, 2026: Short sales 48.4%
  • Nov 4, 2026: Short sales 56.2%
  • Nov 5, 2026: Short sales 49.6%
  • Nov 6, 2026: Short sales 70.4%
  • Nov 9, 2026: Short sales 61%
  • Nov 10, 2026: Short sales 59.9%
  • Nov 11, 2026: Short sales 50.7%
  • Nov 12, 2026: Short sales 61.5%
  • Nov 13, 2026: Short sales 49.3%
  • Nov 16, 2026: Short sales 55.7%
  • Nov 17, 2026: Short sales 57.6%
  • Nov 18, 2026: Short sales 56%
  • Nov 19, 2026: Short sales 56.1%
  • Nov 20, 2026: Short sales 67.8%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

3.99M Insiders' shares3.27% Of the company
  • Alexander Mark SchobelChief Innovation/Tech Officer
    Directly984.5K
  • Daniel BarberPresident and CEO
    Directly627.3K
  • Lori J BraenderChief Legal Officer
    Directly442.9K
  • A Ernest Toth JrChief Financial Officer
    Directly376.1K
  • Peter E. BoydChief People Officer
    Directly284.0K
  • Carl N KrausChief Medical Officer
    Directly282.5K
  • Melina CioffiSVP, Regulatory Affairs
    Directly274.9K
  • Sherry KorczynskiChief Commercial Officer
    Directly235.7K
  • Cassie JungChief Operating Officer
    Directly208.8K
  • John CochranDirector
    Directly161.7K
  • Matthew W. DavisChief Development Officer
    Directly87.5K
  • Richard J DalyDirector
    Directly28.0K
  • Julie KropDirector
    Directly–

A lower bound: it counts only the 13 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

9 ETFs holding it0.10% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.10%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.02%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.02%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.00%
  • ITOTiShares Core S&P Total U.S. Stock Market ETF
    Weight in the fund0.00%
  • IWViShares Russell 3000 ETF
    Weight in the fund0.00%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%

9 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

185 Managers, Q2 2026$300M Value of their positions
  • Q3 2025: Managers 152
  • Q4 2025: Managers 178
  • Q1 2026: Managers 183
  • Q2 2026: Managers 185

Institutional investors by quarter

The fund managers holding AQST, quarter by quarter, from Q3 2018 to Q2 2025, 28 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 185 managers held 72.03M shares, worth $300M. During the quarter 22 opened a position, 20 closed one, 66 added and 45 trimmed.

The largest holders, Q2 2026

  • Bratton Capital Management
    In the quarter
  • BlackRock
    In the quarter+7.5%
  • Rtw Investments
    In the quarter
  • Vanguard Capital Management
    In the quarter+3.2%
  • Federated Hermes
    In the quarter+5.9%
  • State Street
    In the quarter+15%
  • Geode Capital Management
    In the quarter+8.9%
  • Samsara Biocapital
    In the quarter
  • Bank of America
    In the quarter-31%
  • Sio Capital Management
    In the quarter-23%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Aquestive Therapeutics's filings show?

Who buys and sells is one part of Aquestive Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about AQST's shareholders

Didn't find what you were looking for?

Ask us
Have AQST's insiders bought or sold?

From Jun 9, 2026 to Nov 16, 2026 Aquestive Therapeutics's insiders bought $99.3K and sold $734.1K of shares on the market. 100% of the sales were under set 10b5-1 plans.

Which well-known managers hold AQST?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $5.4M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.